Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
CATALYST Trial, Mifepristone, and Hypercortisolism in T2D, with John Buse, MD, PhD
In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, speak with John Buse, MD, PhD, of the University of North Carolina School of Medicine, about the treatment phase of the CATALYST trial.Findings from the phase 4 CATALYST trial suggest that mifepristone (Korlym), a glucocorticoid receptor antagonist, significantly improves glycemic control, reduces body weight, and lowers waist circumference in patients with hypercortisolism and difficult-to-control type 2 diabetes—offering a promising therapeutic…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.